<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Adaptive Designs | CSE Tracker</title>
    <link>https://master--youthful-lamport-190a0e.netlify.app/tag/20220201adaptive-designs/</link>
      <atom:link href="https://master--youthful-lamport-190a0e.netlify.app/tag/20220201adaptive-designs/index.xml" rel="self" type="application/rss+xml" />
    <description>Adaptive Designs</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Tue, 01 Feb 2022 08:00:00 -0700</lastBuildDate>
    <image>
      <url>https://master--youthful-lamport-190a0e.netlify.app/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>Adaptive Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/tag/20220201adaptive-designs/</link>
    </image>
    
    <item>
      <title>IQVIA Webinar: Adaptive Trial Design – Better Development Decisions Using Adaptive Trials </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20220201iqvia-webinar-adaptive-trial-design-better-development-decisions-using-adaptive-trials/</link>
      <pubDate>Tue, 01 Feb 2022 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20220201iqvia-webinar-adaptive-trial-design-better-development-decisions-using-adaptive-trials/</guid>
      <description>&lt;p&gt;&lt;strong&gt;3 Key take-aways&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;The added value of adaptive trial designs can be measured&lt;/li&gt;
&lt;li&gt;Adaptive trials quicken decision-making&lt;/li&gt;
&lt;li&gt;Most trials should have an adaptive component&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Adaptive Design with Bayesian Informed Interim Decisions </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20211109adaptive-design-with-bayesian-informed-interim-decisions/</link>
      <pubDate>Tue, 09 Nov 2021 09:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20211109adaptive-design-with-bayesian-informed-interim-decisions/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;Cytel CMO Webinar Series&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Strategic choices in clinical development - CMO round-table&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/wcc/r/3389677/D7386569DB58480805FC46F12F221952?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Developing Companion Diagnostics: Biotech and MedTech partnership&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/wcc/r/3405536/E8007A871DD585A90735EAEC08475C0A?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Estimand: does it add value to my clinical trial?
&lt;a href=&#34;https://event.on24.com/wcc/r/3407955/B9CEBBC2D1CD7475A98B4CE748C38146?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Phase 1 beyond 3+3: CMO round table
&lt;a href=&#34;https://event.on24.com/wcc/r/3407958/DF0201AD7DB5AF14F10EEB57547F3F80?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Adaptive design with Bayesian Informed Interim Decisions
&lt;a href=&#34;https://event.on24.com/wcc/r/3407935/EB492604B2707711E13FE6DEFB7E3187?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Bayesian trials in drug development: Multidisciplinary Round Table
&lt;a href=&#34;https://event.on24.com/wcc/r/3407963/B770E479A673DEE2EDBD4E70020FA689?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Optimizing Decision on Multiple Endpoints in Clinical Trials
&lt;a href=&#34;https://event.on24.com/wcc/r/3431608/F45430540E15A6842D9B1642161A6F2A?mode=login&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;[Replay]&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Adaptive 2-in-1 Design and Extensions </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20211022adaptive-2-in-1-design-and-extensions/</link>
      <pubDate>Fri, 22 Oct 2021 14:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20211022adaptive-2-in-1-design-and-extensions/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt;&lt;em&gt;ASA San Diego Chapter Webinar&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p&gt;The 2-in-1 adaptive design allows seamless expansion of an ongoing Phase 2 trial into a Phase 3 trial to expedite a drug development program. Under a mild assumption that is expected to generally hold in practice, the trial can be tested at the full alpha level with or without expansion. The endpoint used for expansion decision can be the same as or different from the primary endpoints, and there is no restriction on the expansion bar. Due to its flexibility and robustness, it has drawn immediate attention to academic researchers and industry practitioners. The design has been substantially extended in the literature and successfully implemented in multiple trials.&lt;/p&gt;
&lt;p&gt;In this presentation, we will discuss about decision on the expansion bar as well as various extensions of the 2-in-1 design.&lt;/p&gt;
&lt;p&gt;A live Q&amp;amp;A and networking will follow after the presentation.&lt;/p&gt;
&lt;p&gt;Reference: Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., &amp;amp; Tse, A. (2018). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. Contemporary clinical trials, 64, 238-242.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Adventures in Statistics Lecture Series by Professor Donald A. Berry </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210928adventures-in-statistics-lecture-series-by-professor-donald-a-berry/</link>
      <pubDate>Tue, 28 Sep 2021 14:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210928adventures-in-statistics-lecture-series-by-professor-donald-a-berry/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: salmon;&#34;&gt; &lt;em&gt;A seminar series on Sep 28, Oct 26, and Nov 30&lt;/em&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p&gt;A three-part lecture series focused on Bayesian adaptive clinical trials over time.&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Part One – From multi-armed bandit strategies to designs for phase 3 adaptive Bayesian platform clinical trials. 9/28/2021&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Part Two – How regulators and journals came to accept and perhaps even embrace adaptive Bayesian clinical trials. 10/26/2021&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Part Three – Adaptive Bayesian platform trials and the role of regulators in promoting clinical trials with “complex innovative designs.” 11/30/2021&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Adaptive Designs for Optimal Dose Determination in I-O and Cell Therapy</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210903adaptive-designs-for-optimal-dose-determination-in-i-o-and-cell-therapy/</link>
      <pubDate>Fri, 03 Sep 2021 06:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210903adaptive-designs-for-optimal-dose-determination-in-i-o-and-cell-therapy/</guid>
      <description>&lt;p&gt;&lt;em&gt;Part of the Fifth Boston Pharmaceutical Symposium&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Immuno-oncology (I-O) and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients. It is critical to identify optimal dose and patient populations in early phase of trials thus improving the probability of success in pivotal trials. Given the complex mechanism interacting with immune system and patient heterogeneity, the conventional oncology dose finding design may not serve the purpose. For example, it is questionable to believe the monotone relationship between dose level and safety/efficacy, which will likely result in inappropriate dose selection using designs with monotone assumption. Additionally, considering the immune system pathway, designs ignoring the heterogeneity of the patient populations may provide misleading dose decisions, which could be either unsafe or lead to selection mistakes for targeted population.&lt;/p&gt;
&lt;p&gt;This seminar will provide a review and discussion of innovative designs for optimal dose determination in I-O and Cell Therapy from the following perspectives&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Dose finding focusing on DLT&lt;/li&gt;
&lt;li&gt;Dose finding considering late onset toxicity&lt;/li&gt;
&lt;li&gt;Dose finding in basket trials with borrowing scheme&lt;/li&gt;
&lt;li&gt;Optimal dose identification design incorporating both safety and efficacy endpoints&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Analyzing Clinical Trials for Personalized Medicine via Bayesian Adaptive Design (DACTPerM)</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210611analyzing-clinical-trials-for-personalized-medicine-via-bayesian-adaptive-design-dactperm/</link>
      <pubDate>Fri, 11 Jun 2021 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210611analyzing-clinical-trials-for-personalized-medicine-via-bayesian-adaptive-design-dactperm/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cytel Webinar: Information Borrowing in Clinical Trials - Methods for Basket Trials and External Data</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210525cytel-webinar-information-borrowing-in-clinical-trials-methods-for-basket-trials-and-external-data/</link>
      <pubDate>Tue, 25 May 2021 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20210525cytel-webinar-information-borrowing-in-clinical-trials-methods-for-basket-trials-and-external-data/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Data Monitoring and Adaptive Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</link>
      <pubDate>Tue, 15 Dec 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20201215data-monitoring-and-adaptive-designs/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Cytel’s New Horizons Webinar Series</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</link>
      <pubDate>Mon, 05 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/conference/20201005cytel-s-new-horizons-webinar-series/</guid>
      <description>&lt;p&gt;&lt;span style=&#34;color: green;&#34;&gt;&lt;em&gt;Replay links available&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Increasing the Power of Platform Trials: Efficient Multi-Arm Multi-Stage Adaptive Designs&lt;/strong&gt;&lt;br&gt;
Speaker: Cyrus Mehta&lt;br&gt;
October 5, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2713671&amp;amp;sessionid=1&amp;amp;key=DEC35F5F99E3B346CD3428FB63E00EA1&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;The Value of Detailed Statistical Trial Simulations – A Case Study for Rare Diseases&lt;/strong&gt;&lt;br&gt;
Speaker: Ursula Garczarek&lt;br&gt;
October 26, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2754403&amp;amp;sessionid=1&amp;amp;key=5190486304A26AF8A168A9EB5762E412&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;Key Design Considerations for Adaptive Platform Trials&lt;/strong&gt;&lt;br&gt;
Speaker: Jay Park&lt;br&gt;
November 2, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803072&amp;amp;sessionid=1&amp;amp;key=B00AA58DD8F16FD72214ED83EAE3F56C&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;&lt;strong&gt;AI in Clinical Research: Prediction and Causal Inference&lt;/strong&gt;&lt;br&gt;
Speaker: Alind Gupta&lt;br&gt;
November 9, 2020&lt;br&gt;
&lt;a href=&#34;https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;amp;mode=login&amp;amp;eventid=2803079&amp;amp;sessionid=1&amp;amp;key=F30F710608E4E55C3E02D0193E42FEAB&amp;amp;regTag=&amp;amp;V2=false&amp;amp;sourcepage=register&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Replay&lt;/a&gt;&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Advancing Early Stage Oncology Research with Adaptive Designs and Master Protocols</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</link>
      <pubDate>Tue, 29 Sep 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200929advancing-early-stage-oncology-research-with-adaptive-designs-and-master-protocols/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;
&lt;p&gt;Improved determination of the maximum tolerated dose, comparing different designs for dose selection&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Advantages of basket trial design for finding the most appropriate indication(s)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Current regulatory positions and outlook of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human use (ICH)&lt;/p&gt;
&lt;/li&gt;
&lt;li&gt;
&lt;p&gt;Operational implications of different designs&lt;/p&gt;
&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Adaptive Designs for Phase II Clinical Trials </title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818adaptive-designs-for-phase-ii-clinical-trials/</link>
      <pubDate>Tue, 18 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200818adaptive-designs-for-phase-ii-clinical-trials/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;Important aspects of Phase II trials designs to consider&lt;/li&gt;
&lt;li&gt;Practical worked examples of&lt;/li&gt;
&lt;li&gt;MCP-Mod (continuous outcome)&lt;/li&gt;
&lt;li&gt;MCP-Mod (binary outcome)&lt;/li&gt;
&lt;li&gt;Fleming GST (binary outcome)&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>Adaptive and Bayesian Designs for Dose-Finding</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200805adaptive-and-bayesian-designs-for-dose-finding/</link>
      <pubDate>Wed, 05 Aug 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200805adaptive-and-bayesian-designs-for-dose-finding/</guid>
      <description>&lt;p&gt;Finding the right dose in Phase 2 gives a potential new therapy its best chance to demonstrate efficacy during Phase 3. A well-executed dose-ranging trial therefore has the potential to alter the course of the entire clinical development program. This webinar demonstrates how adaptive and Bayesian techniques can be implemented for optimal dose-finding.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Flexible Clinical Trial Design - Survival, Stepped-Wedge &amp; MAMS Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200723flexible-clinical-trial-design-survival-stepped-wedge-mams-designs/</link>
      <pubDate>Thu, 23 Jul 2020 00:00:00 +0000</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200723flexible-clinical-trial-design-survival-stepped-wedge-mams-designs/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Flexible Survival Analysis Designs&lt;/strong&gt;&lt;br&gt;
Non-proportional hazards and other complex survival curves have become of increasing interest, due to being commonly seen in immunotherapy development. This has led to interest in assessing the robustness of standard methods and alternative methods that better adapt to deviations.&lt;/p&gt;
&lt;p&gt;In this webinar, we will look at power analysis assuming complex survival curves and the weighted log-rank test as one candidate model to deal with a delayed survival effect.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Stepped-Wedge designs&lt;/strong&gt;&lt;br&gt;
Cluster-randomized designs are often adopted when there is a high risk of contamination if cluster members were randomized individually. Stepped-wedge designs are useful in cases where it is difficult to apply a particular treatment to half of the clusters at the same time.&lt;/p&gt;
&lt;p&gt;In this webinar, we will introduce stepped-wedge designs and provide an insight into the more complex, flexible randomization schedules available.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Multi-Arm Multi-Stage (MAMS)&lt;/strong&gt;&lt;br&gt;
MAMs designs provide the ability to assess more treatments in less time than could be done with a series of two-arm trials and can offer smaller sample size requirements when compared to that required for the equivalent number of two-arm trials.&lt;/p&gt;
&lt;p&gt;In this webinar, we will look at the design of a Group Sequential MAMS design and explore its design requirements.&lt;/p&gt;</description>
    </item>
    
    <item>
      <title>Introduction to Population Enrichment Trial Designs</title>
      <link>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715introduction-to-population-enrichment-trial-designs/</link>
      <pubDate>Wed, 15 Jul 2020 08:00:00 -0700</pubDate>
      <guid>https://master--youthful-lamport-190a0e.netlify.app/webinar/20200715introduction-to-population-enrichment-trial-designs/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
